The effects of gonadotrophin releasing hormone analogues in prostate cancer are mediated through specific tumour receptors
1990

Effects of GnRH Analogues on Prostate Cancer

Sample size: 76 publication Evidence: moderate

Author Information

Author(s): A. Qayuml, W. Gullick, R.C. Clayton, K. Sikora, J. Waxman

Primary Institution: Royal Postgraduate Medical School, Northwick Park Hospital, London, UK

Hypothesis

The study investigates the direct regulatory effect of gonadotrophin releasing hormone (GnRH) analogues on prostatic cancer cell growth.

Conclusion

GnRH analogues can stimulate the growth of androgen-sensitive prostatic cancer cells and may play a role in prostatic epithelial cell growth in vivo.

Supporting Evidence

  • High affinity binding of a GnRH analogue was observed in the human androgen-sensitive prostatic cancer cell line LNCaP.
  • Nineteen of 22 malignant tumors exhibited high affinity GnRH-analogue binding.
  • Seventy-six human benign and malignant tumors were assayed following surgical resection.

Takeaway

This study found that a hormone called GnRH can help prostate cancer cells grow, which is surprising because we usually think hormones slow down cancer.

Methodology

The study involved binding assays and biological response studies using human prostatic cancer cell lines and biopsy samples.

Limitations

The study does not clarify whether GnRH itself has mitogenic activity or its synergy with other growth factors.

Participant Demographics

The study included 76 human benign and malignant prostate tumors.

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication